Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:BCAB

BioAtla Q4 2025 Earnings Results & Report

BioAtla logo
$1.36 +0.06 (+4.62%)
As of 10/16/2026 03:50 PM Eastern

BioAtla beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 31, 2026. The company reported EPS of -$8.00 versus the -$18.00 consensus estimate, while revenue of $2.00 million topped the $0.70 million estimate by $1.30 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

BioAtla EPS Results

Actual EPS
-$8.00
Consensus EPS
-$18.00
Beat/Miss
Beat by +$10.00
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

BioAtla Revenue Results

Actual Revenue
$2.00 million
Expected Revenue
$0.70 million
Beat/Miss
Beat by +$1.30 million
YoY Revenue Growth
N/A

Upcoming Earnings

BioAtla's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BioAtla's Q4 2025 Annual reportAnnual report
(10-K)

BioAtla Q4 2025 Earnings FAQ

BioAtla (NASDAQ:BCAB) reported earnings of -$8.00 per share for Q4 2025, beating the consensus estimate of -$18.00. The report was announced on Tuesday, March 31, 2026.

BioAtla reported revenue of $2.00 million for Q4 2025, against a consensus estimate of $0.70 million.

BioAtla's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for BioAtla on the company's earnings history page.

BioAtla Earnings Headlines

Contrasting BioAtla (NASDAQ:BCAB) and Bicycle Therapeutics (NASDAQ:BCYC)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110357
BioAtla Announces $40 Million Oncology SPV Investment Deal
May 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BCAB/pressreleases/36851340/bioatla-announces-40-million-oncology-spv-investment-deal/
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.tc pixel
October 18 at 1:00 AM  |  Paradigm Press (Ad)
BioAtla Announces Share Consolidation
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266037/0/en/bioatla-announces-share-consolidation.html
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266019/0/en/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights.html
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value
March 2, 2026  |  quiverquant.comQ
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB) was a biotechnology company focused on developing antibody-based cancer therapies. The company’s research centered on its Conditionally Active Biologics (CAB) platform, which was designed to create therapeutic antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissue.

BioAtla’s development pipeline included antibody-drug conjugates and other immuno-oncology candidates. Its leading programs included mecbotamab vedotin, also known as BA3011, an antibody-drug conjugate targeting AXL, and ozuriftamab vedotin, or BA3021, an antibody-drug conjugate directed at ROR2. The company evaluated these candidates in clinical studies for solid tumors and other cancers.

Founded in 2007 and headquartered in San Diego, California, BioAtla advanced its programs through clinical development and collaborations intended to support the development of targeted cancer medicines. The company later reduced operations and pursued strategic alternatives after encountering clinical and financial challenges. Public disclosures indicated that BioAtla ultimately wound down its business, so its historical pipeline and platform provide the primary basis for describing the company.

View BioAtla Profile
Earnings Tools